Biosimilar Development

About JSC Pharmstandard

Founded in 2003, JSC Pharmstandard has solidified its position as Russia's leading pharmaceutical manufacturer, driven by a mission to ensure the availability of affordable, high-quality medicines. Its strategy is built on massive-scale generic drug production, a broad portfolio covering over 30 dosage forms, and active support of national healthcare priorities, including import substitution. Recent partnerships with academic institutions and innovation camps underscore its focus on technological modernization within the generics and biosimilars space to maintain market leadership.

About Bora Pharmaceuticals

Bora Pharmaceuticals has established itself as a premier hybrid CDMO and pharmaceutical developer in Asia, achieving significant scale with a market capitalization exceeding $57 billion. The company's strategy successfully integrates high-margin contract services with proprietary drug development, creating a diversified and resilient revenue model. Its core achievements include building PIC/S and FDA-compliant manufacturing facilities, developing a robust pipeline of complex generics and specialty products, and securing a strong position as a critical supply chain partner for multinational pharmaceutical companies.

Therapeutic Areas

Other Immunology, Oncology Drugs